secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001171843-24-002672
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics Q1 revenue up 7% to $40.5M; narrows net loss; reaffirms FY2024 guidance
--------------------------------------------------------------------------------

- Q1 revenue $40.5M (+7% YoY); net loss narrowed to $4.5M from $10.4M; adjusted net income $1.2M ($0.09/dil share).
- Adjusted EBITDA improved to $2.5M from ($1.2M) in Q1 2023; FY2024 adj EBITDA guidance $25-30M (midpoint up >75%).
- Cost reduction initiatives completed, achieving $10M annualized savings; severance costs $0.8M in Q1.
- Business highlights: extended Canadian distribution deal through 2030; >10,000 X-Twist anchors sold; Integrity Implant >200 cases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/0001171843-24-002672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324002672/f8k_050824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer